• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
  • View Item
  •   LillOA Home
  • Liste des unités
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Risk factors for the development of epilepsy ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique: Article original
DOI :
10.1093/neuonc/noz172
PMID :
31498867
Permalink :
http://hdl.handle.net/20.500.12210/75167
Title :
Risk factors for the development of epilepsy in patients with brain metastasis
Author(s) :
Wolpert, Fabian [Auteur]
Lareida, Anna [Auteur]
Terziev, Robert [Auteur]
Grossenbacher, Bettina [Auteur]
Neidert, Marian Christoph [Auteur]
Roth, Patrick [Auteur]
Poryazova, Rositsa [Auteur]
Imbach, Lukas [Auteur]
Le Rhun, Emilie [Auteur]
Weller, Michael [Auteur]
Journal title :
Neuro-Oncology
Abbreviated title :
Neuro-oncology
Publication date :
2019-09-10
ISSN :
1523-5866
Keyword(s) :
prophylaxis
seizure
score
CNS
prevention
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
BACKGROUND: Current guidelines do not recommend primary prophylactic anti-epileptic drug (AED) therapy for patients with brain metastases (BM). Yet, subgroups of patients at high seizure risk might still benefit from ...
Show more >
BACKGROUND: Current guidelines do not recommend primary prophylactic anti-epileptic drug (AED) therapy for patients with brain metastases (BM). Yet, subgroups of patients at high seizure risk might still benefit from prophylaxis. METHODS: We identified 799 patients diagnosed with BM by retrospective screening of our electronic chart system. Candidate risk factors for the development of epilepsy were tested by univariate and multivariate Cox regression models. RESULTS: Epilepsy was diagnosed in 226 of 799 patients (28%). Risk factors for epilepsy in non-operated patients were single BM (P = 0.002, hazard ratio [HR] 3.2, 95% CI: 1.5-6.6) and detection of tumoral hemorrhage (P = 0.008, HR 2.5, 95% CI: 1.3-4.9). Preoperative seizures occurred predominantly in patients with supratentorial BM (P = 0.003, HR 20.78, 95% CI: 2.8-153.4) and lung cancer (P = 0.022; HR 2.0, 95% CI: 1.1-3.6). Postoperative seizures were associated with supratentorial localization (P = 0.017, HR 5.8, 95% CI: 1.4-24.3), incomplete resection (P = 0.005, HR 4.6, 95% CI: 1.6-13.1), and by trend for multiple brain surgeries (P = 0.095, HR 1.9, 95% CI: 0.9-4.0). These risk factors were integrated into a predictive score model for postoperative epilepsy (score sum 0-8). A gradual increase of seizure rates along with higher sum score was confirmed post hoc (score 0 = no seizures; score 8 = 48% seizures). Receiver operating characteristic analysis supported diagnostic accuracy (P = 0.00001, area under the curve = 0.75). CONCLUSIONS: Here we have defined risk profiles for the development of BM-related epilepsy and derived a score which might help to estimate the risk of postoperative seizures and identify individuals at risk who might benefit from primary prophylactic AED therapy.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
INSERM
Université de Lille
Collections :
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Submission date :
2022-06-15T13:59:35Z
Université de Lille

Mentions légales
Université de Lille © 2017